PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32075509-8	2021	In contrast, increased activity of AMPK with metformin, AICAR, 2DG, or by gene overexpression did not enhance autophagy but had different effects on Abeta secretion: whereas metformin and 2DG diminished the secreted Abeta levels, AICAR and PRKAA1/AMPK gene overexpression increased them.	Metformin	174-183	amyloid beta (A4) precursor protein	Mus musculus	216-221	
26211973-4	2016	Chronic treatment of db/db mice with antidiabetic drugs such as metformin, glibenclamide and insulin glargine significantly decreased Abeta influx across the BBB determined by intra-arterial infusion of (125)I-Abeta(1-40), and expression of the receptor for advanced glycation end products (RAGE) participating in Abeta influx.	Metformin	64-73	amyloid beta (A4) precursor protein	Mus musculus	134-139	
26211973-4	2016	Chronic treatment of db/db mice with antidiabetic drugs such as metformin, glibenclamide and insulin glargine significantly decreased Abeta influx across the BBB determined by intra-arterial infusion of (125)I-Abeta(1-40), and expression of the receptor for advanced glycation end products (RAGE) participating in Abeta influx.	Metformin	64-73	amyloid beta (A4) precursor protein	Mus musculus	210-215	
27509335-5	2016	Moreover, metformin induces mitochondrial dysfunction and cell death by affecting the level and conformation of Translocase of the Outer Membrane 40 (TOM40), voltage-dependent anion-selective channels 1 (VDAC1) and hexokinase I (HKI), proteins involved in mitochondrial transport of molecules, including Abeta.	Metformin	10-19	amyloid beta (A4) precursor protein	Mus musculus	304-309	
27509335-6	2016	By using biophysical techniques we found that metformin is able to directly interact with Abeta influencing its aggregation kinetics and features.	Metformin	46-55	amyloid beta (A4) precursor protein	Mus musculus	90-95	
34291435-7	2021	Importantly, we find that in the APP/PS1 mouse model of Alzheimer"s disease (AD), activation of CMA by Hsc70 overexpression or Metformin potently reduces the accumulated brain Abeta plaque levels and reverses the molecular and behavioral AD phenotypes.	Metformin	127-136	amyloid beta (A4) precursor protein	Mus musculus	176-181	
34311050-9	2021	Compared with controls, metformin-treated APP23-ob/ob mice had significantly reduced Abeta levels in the cerebral cortex (p < .05) and hippocampus (p < .05) and increased levels of IDE in the hippocampus (p < .01).	Metformin	24-33	amyloid beta (A4) precursor protein	Mus musculus	85-90	
34311050-10	2021	Our results indicate that metformin attenuates the severity of CAA by enhancing Abeta-cleaving IDE expression.	Metformin	26-35	amyloid beta (A4) precursor protein	Mus musculus	80-85	
32377293-0	2020	Metformin Ameliorates Abeta Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer"s Disease.	Metformin	0-9	amyloid beta (A4) precursor protein	Mus musculus	22-27	
32377293-5	2020	In this study, we tried to figure out whether metformin could activate insulin-degrading enzyme (IDE) to ameliorate Abeta-induced pathology.	Metformin	46-55	amyloid beta (A4) precursor protein	Mus musculus	116-121	
32377293-10	2020	In addition, metformin obviously reduced the Abeta level in the brain of APP/PS1 mice.	Metformin	13-22	amyloid beta (A4) precursor protein	Mus musculus	45-50	
32538851-8	2020	DNLA and metformin treatments decreased amyloid-beta1-42, AbetaPP, PS1, and BACE1, while increasing IDE and neprilysin for Abeta clearance.	Metformin	9-18	amyloid beta (A4) precursor protein	Mus musculus	58-63